Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database^*

References

• Diestelhort JS, Hughes GM. Open-angle glaucoma. Am Fam Phys 2003;67:1937–44
   PubMed Web of Science ®Google Scholar
• Hattenhauer MG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105:2099–104
   PubMed Web of Science ®Google Scholar
• Broman AT, Quigley HA. The number of people with glaucoma worldwide in 2010 and Br J Ophthalmol 2006;90: 253–4
   Google Scholar
• Coyle D, Drummond M. The economic burden of glaucoma in the UK. The need for a far-sighted policy. Pharmacoeconomics 1995;7:484–9
   Google Scholar
• Kobelt G, Jonsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998;236:811–21
   PubMed Web of Science ®Google Scholar
• Denis P, Lafuma A, Berdeaux G. Medical predictive factors of glaucoma treatment costs. J Glaucoma 2004;13:283–90
   PubMed Web of Science ®Google Scholar
• Jönsson B, Krieglstein G. Primary open-angle glaucoma-differences in international treatment patterns and costs. Oxford: Isis Medical Media, 1998
   Google Scholar
• Kooner KS, Zimmerman TJ. The cost of antiglaucoma medications. Ann Ophthalmol 1987;19:327–8
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch of Ophthalmol 2002;120:701–13
   PubMed Web of Science ®Google Scholar
• The European Glaucoma Prevention Study (EGPS) group. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366–75
   Google Scholar
• The AGIS investigators. The Advanced Glaucoma Intervention Study (AGIS). Report #13: Comparison of treatment outcomes within race: 10-year results. Ophthalmology 2004;111: 651–64
   Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–79
   Google Scholar
• Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429–40
   Google Scholar
• Suzuki ER Jr, Franklin LM, da Silva LJ, et al. Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. Curr Med Res Opin 2006;22:1799–805
   PubMed Web of Science ®Google Scholar
• Chiselita D, Antohi I, Medvichi R, et al. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Oftalmologia 2005;49:39–45
   PubMedGoogle Scholar
• Parmaksiz S, Yuksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73–80
   PubMed Web of Science ®Google Scholar
• Hjelmgren J, Berggren F, Andersson D. Health Economics guidelines – Similarities, differences and some implications. Values in Health 2001;4:225–50
   Google Scholar
• Covert D, Robin AL. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 2006;22:971–6
   PubMed Web of Science ®Google Scholar
• Deschaseaux-Voinet C, Lafuma A, Berdeaux G. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. J Med Econom 2003:6:69–78
   Google Scholar
• Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28–33
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598–606
   PubMed Web of Science ®Google Scholar
• http://www.gprd.com/home/
   Google Scholar
• Yue LQ. Statistical and regulatory issues with the application of propensity score analysis to nonrandomized medical device clinical studies. J Biopharm Stat 2007;17:1–13; discussion 15–7, 19–21, 23–7 passim
   Google Scholar
• British National Formulary. London BMJ Publishing Group, 2007
   Google Scholar
• Statistics of OECD http://www.oecd.org/
   Google Scholar
• Curtis L, Netten A. Units costs of health and social care 2005 PSSRU University of Kent. (http://www.pssru.ac.uk/)
   Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR). http://www.emea.europa.eu/htms/human/epar/a.htm
   Google Scholar
• Robin AL, Covert D Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863–8
   Google Scholar
• Rouland JF, Le Pen C, Gouveia Pinto, et al. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open glaucoma in 4 European countries. PharmacoEconom 2003;21:201–13
   PubMed Web of Science ®Google Scholar